Clinical Trial Update: The Study of ICP-248 in Patients With Mature B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study of ICP-248 in patients with mature B-cell malignancies is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mature B-cell Malignancies

Drugs mentioned

• ICP-248

Snippet

Sponsor: Beijing InnoCare Pharma Tech Co., Ltd. | Conditions: Hematological Malignancies | Phase 1 | Status: RECRUITING